Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor

Korean Journal of Internal Medicine

Volumn 28, Issue 2, 2013, Pages 174-179

  Chung, Keun Bum ^a   Lee, Eun Young ^a   Im, Jong Pil ^a   Han, Sung Koo ^a   Yim, Jae Joon ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Mycobacterium; Tuberculosis; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; ETANERCEPT; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG RESPONSE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LIVER FUNCTION; LUNG TUBERCULOSIS; MALE; MEDICAL RECORD REVIEW; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPUTUM CULTURE; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOUS PLEURISY; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875530394     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2013.28.2.174     Document Type: Article

References (27)

1. WHO global tuberculosis control report 2010: summary. Cent Eur J Public Health 2010;18:237.
2. Lin PL, Plessner HL, Voitenok NN, Flynn JL. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc 2007;12:22-25.
3. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-377.
4. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20.
5. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
6. Serbina NV, Flynn JL. Early emergence of CD8(+) T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice. Infect Immun 1999;67:3980-3988.
7. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129.
8. Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001;166:6728-6734.
9. Bean AG, Roach DR, Briscoe H, et al. Structural def iciencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999;162:3504-3511.
10. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-572.
11. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-1992.
12. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376.
13. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-3022.
14. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-2127.
15. Singh JA, Wells GA, Christensen R, et al. Adverse ef fects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;(2):CD008794.
16. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39:1254-1255.
17. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of inf liximab therapy. Arthritis Rheum 2004;50:372-379.
18. Korean National Tuberculosis Association. Trend of case notification rate per 100,000 by year, 2004-2011 [Internet]. Seoul (KR): Korean National Tuberculosis Association, c2011 [cited 2013 Feb 1]. Available from: http://www.knta.or.kr.
19. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with inf liximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
20. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010;50:1288-1299.
21. Morris MI, Daly JS, Blumberg E, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant 2012;12:2288-2300.
22. Ersan S, Celik A, Atila K, et al. Tuberculosis in renal transplant recipients. Ren Fail 2011;33:753-757.
23. Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002;61:251-253.
24. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206.
25. Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev Clin Immunol 2011;7:329-340.
26. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J 2012;39:807-819.
27. Joint Committee for the Development of Korean Guidelines for Tuberculosis; Korea Centers for Disease Control and Prevention. Korean Guidelines for Tuberculosis. 1st ed. Cheongwon: Korea Centers for Disease Control and Prevention, 2011.